Study on the Difference of Plasma microRNA Expression in Patients With Genetic Susceptibility to Mental Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Schizophrenia (Schizophrenia,Sc), biphasic affective disorder (Bipolar disorder,BPD), major depression (major depressive disorder,MDD), anxiety disorder (Anxiety disorder,An) and other mental disorders have obvious family aggregation, with heritability of 60 -90%. This kind of common mental illness seriously affects the psychosomatic health and quality of life of patients, and places a great mental and economic burden on the society and family. At present, the diagnosis of mental illness is mainly based on clinical symptoms. With the development of molecular biology, genomics has become a new way to study mental illness. MicroRNA (miRNA) is a class of eukaryotic endogenously non-coding single-stranded RNA, which can regulate gene expression by binding to specific mRNA or regulating the protein translation process of specific mRNA. MiRNA widely exists in plasma and serum, and the type and quantity of miRNA in plasma and serum change with different physiological and disease conditions. It is reported that the expression profile of miRNA in brain tissue of schizophrenia is significantly different from that of normal subjects. In addition, the study found that the specific miRNA detected in peripheral blood can directly reflect the condition of the disease, which may use miRNA in peripheral blood as a clinical biological marker. In order to detect the expression of various miRNA in plasma, high throughput miRNA chip detection has become the first choice for primary screening. In this study, the investigators intend to detect the difference of miRNA expression in peripheral blood of different types of schizophrenia by high throughput miRNA chip, and analyze the correlation between them. It is hoped to provide the basis for the diagnosis and occurrence and development of clinical psychotic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Imaging Genetic Study of Schizophrenia and Family

NCT01259232

Schizophrenia

UNKNOWN

Genetic Aspects of Neurologic and Psychiatric Disorders

NCT00001544

Attention Deficit Disorder With Hyperactivity Bipolar Disorder Mental Disorder Diagnosed in Childhood +2 more

COMPLETED

A Genetic Family Cohort Study of Bipolar Disorder in Chinese Han Population

NCT04024553

Bipolar Disorder

UNKNOWN

Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study

NCT00300820

Bipolar Disorder (BD) Bipolar

COMPLETED

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

NCT01149551

Schizophrenia Bipolar Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasma microRNA in Patients With Genetic Susceptibility to Mental Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.